喷昔洛韦联合膦甲酸钠治疗带状疱疹的回顾性分析

Retrospective analysis of penciclovir combined with foscarnet sodium in the treatment of herpes zoster

目的 探讨喷昔洛韦联合膦甲酸钠治疗带状疱疹的临床疗效.方法 收集2014年1月至2016年8月在天津医科大学总医院皮肤科住院的135例带状疱疹患者临床资料,其中64例给予喷昔洛韦联合膦甲酸钠抗病毒,其余71例仅给予喷昔洛韦.整理两组患者一般资料、止疱时间、结痂时间、疼痛开始缓解时间、疼痛明显缓解时间、不良反应及是否出现带状疱疹后神经痛,并进行统计分析.结果 两组患者一般资料比较差异无统计学意义,（均P 〉0.05,数值为性别0.086、年龄0.062、发病部位0.284、治疗前病程0.387、治疗前病情评分0.225）,而止疱时间、结痂时间、疼痛开始缓解时间、疼痛明显缓解时间,联合用药组均较喷昔洛韦组短（均P〈0.001）,且带状疱疹后神经痛出现例数少（P =0.013）.两组不良反应比较差异无统计学意义（P=0.928）.结论 喷昔洛韦联合膦甲酸钠治疗带状疱疹起效快,带状疱疹后神经痛发生率低,相比单一喷昔洛韦抗病毒治疗未增加不良反应,是治疗带状疱疹的可靠手段.

Objective To evaluate the therapeutic efficacy of penciclovir combined with foscarnet sodium in the treatment of herpes zoster.Methods The clinical datas of 135 herpes zoster patients from the ward of Department of Dermatology,Tianjin Medical University General Hospital were collected.Among them 64 patients received penciclovir and foscarnet sodium,and the remaining 71 patients only received penciclovir alone.Their general information,the time for vesicle stopped emerging,rash began to scab,pain to relief obviously,the adverse reaction and if they got the postherpetic neuralgia were recorded and included into statistical analysis.Results The general information showed no significant differences between the 2 groups（all P 〉0.05）.The time for vesicle stopped emerging,rash began to scab,pain to relief obviously in combination group was shorter than the penciclovir group （all P 〈 0.001）.The number of patients who developed postherpetic neuralgia of combination group was fewer than that of penciclovir group（P =0.013）.There was no statistical significance between the 2 groups the adverse reaction（P =0.928）.Conclusions The penciclovir and foscarnet sodium combination therapy showed rapid therapeutic effects on herpes zoster patients,the incidence of postherpetic neuralgia was low,and there was no more side effects than penciclovir alone therapy.The combined therapy may be a reliable way to treat herpes zoster.